Erschienen in:
03.09.2020 | ASO Author Reflections
ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma
verfasst von:
Timothy E. Newhook, MD, Ching-Wei D. Tzeng, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
Pancreatic ductal adenocarcinoma remains a complex disease in which incremental gains in survival have been difficult to achieve, even within the patient population with putatively localized disease. Because of this struggle for any improvements in survival outcomes, scrutiny of all phases of care, including the perioperative period, has led to increased focus on reducing major complications and minimizing the surgical stress response. Along these lines, a prior report found that a single dose of intravenous dexamethasone used for prophylaxis against postoperative nausea and vomiting reduced complications and nearly doubled the survival rate of resected patients.
1 As a component of many chemotherapy regimens and an immunomodulator, it is possible that dexamethasone may have short-term and long-term positive effects on PDAC surgery. However, we hypothesized that a single dose of dexamethasone would not supersede the importance of underlying biologic factors and major complications. …
